Company Overview and News
In this photo, taken Sept. 29, 2015, Elon Musk, CEO of Tesla Motors Inc., talks about the Model X car at the company’s headquarters, in California. In tweet on Monday, July 3, 2017, Musk announced that the Model 3 car for the masses will go on sale on Friday, July 7. (Photo by MARCIO JOSE SANCHEZ / AP)
Tesla just signed a memorandum of intent with Shanghai to build a 500k EV per year Gigafactory 3 in China = ~$20B/yr revenue.
Tesla (NASDAQ:TSLA) has hit a major milestone, by delivering 200,000 electric cars to U.S. customers. That’s obviously good news for the company and TSLA stock investors. However, that success comes with a downside.
GM.WS.A GM.WS.B GM.WS.C TSLA GM GM.WSB
Two weeks ago, Tesla opened up Model 3 orders to all US and Canada-based reservation holders.
At that conversion ratio, the current 420,000 backlog translates into 126,000 deliveries and only 36,000 vehicles at the current ASP.
At the end of June, Tesla (NASDAQ:TSLA) hit a major milestone. While the TSLA stock price didn’t reflect it, producing 5,000 Tesla Model 3 vehicles in a week was a big accomplishment for the company. But is the new sedan for the masses yet? It’s getting there.
2017-10-09 - Asif
Tesla Motors's mission is to accelerate the world’s transition to sustainable energy. The company design, develop, manufacture, lease and sell high-performance fully electric vehicles, solar energy generation systems and energy storage products. The company also offer maintenance, installation, operation and other services related to its products. Automotive Tesla Motors production vehicle fleet includes Model S premium sedan and Model X sport utility vehicle, which are its highest-performance and most capable vehicles, and beginning in July 2017, its Model 3, a lower priced sedan designed for the mass market. The company continue to enhance its vehicle offerings with enhanced Autopilot options, Internet connectivity and free over-the-air software updates. The company continually deploy its internally developed software into the vehicle fleet, depending on the hardware of the vehicle, to provide additional safety and convenience features. The company are also actively working ...
21h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
23h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TSLA / Tesla Motors, Inc. on message board site Silicon Investor.
|Tesla EVs - TSLA||WTSLA: Wet Seal, Inc.|
as of ET